Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:PKI

Revvity (PKI) Stock Price, News & Analysis

Revvity logo

About Revvity Stock (NYSE:PKI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$115.24
$137.11
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
851,117 shs
Market Capitalization
$14.57 billion
P/E Ratio
15.01
Dividend Yield
0.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

Revvity, Inc. (RVTY)
2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
Revvity Inc PKI
See More Headlines

PKI Stock Analysis - Frequently Asked Questions

Revvity, Inc. (NYSE:PKI) posted its earnings results on Thursday, May, 11th. The medical research company reported $1.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analysts' expectations of $686.30 million. Revvity had a trailing twelve-month return on equity of 11.17% and a net margin of 28.94%.

Revvity's Board of Directors approved a stock buyback program on Thursday, May 11th 2023, which allows the company to buy back $600,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 4.1% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its stock is undervalued.

Revvity subsidiaries include BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and others.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/11/2023
Today
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:PKI
Employees
16,700
Year Founded
1937

Profitability

Trailing P/E Ratio
15.01
Forward P/E Ratio
N/A
P/E Growth
0.5
Net Income
$569.18 million
Pretax Margin
13.81%

Debt

Sales & Book Value

Annual Sales
$3.31 billion
Price / Cash Flow
9.88
Book Value
$58.49 per share
Price / Book
N/A

Miscellaneous

Free Float
125,755,000
Market Cap
$14.57 billion
Optionable
Optionable
Beta
1.10

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:PKI) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners